Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume -, Issue -, Pages JCO.21.01210
Publisher
American Society of Clinical Oncology (ASCO)
Online
2021-07-27
DOI
10.1200/jco.21.01210
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Acalabrutinib in Treatment-Naïve Chronic Lymphocytic Leukemia
- (2021) John C. Byrd et al. BLOOD
- ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
- (2020) Paolo Ghia et al. JOURNAL OF CLINICAL ONCOLOGY
- Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial
- (2020) Jeff P Sharman et al. LANCET
- A RANDOMIZED PHASE 3 TRIAL OF ZANUBRUTINIB VERSUS IBRUTINIB IN SYMPTOMATIC WALDENSTRÖM MACROGLOBULINEMIA:THE ASPEN STUDY
- (2020) Constantine S. Tam et al. BLOOD
- Ibrutinib-Mediated Atrial Fibrillation Due to Inhibition of CSK
- (2020) Ling Xiao et al. CIRCULATION
- Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis
- (2019) Daniel Caldeira et al. PLoS One
- Long-term follow-up of the RESONATE™ phase 3 trial of ibrutinib versus ofatumumab
- (2019) John C. Byrd et al. BLOOD
- Targeting BTK in CLL: Beyond Ibrutinib
- (2019) David A. Bond et al. Current Hematologic Malignancy Reports
- Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia
- (2019) Thomas J. Kipps et al. Clinical Lymphoma Myeloma & Leukemia
- Hypertension and incident cardiovascular events following ibrutinib initiation
- (2019) Tyler Dickerson et al. BLOOD
- Cardiovascular Toxicities Associated With Ibrutinib
- (2019) Joe-Elie Salem et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
- (2019) Jan A. Burger et al. LEUKEMIA
- Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results
- (2019) John C. Byrd et al. BLOOD
- Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience
- (2018) Susan O’Brien et al. BLOOD
- Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials
- (2017) Jennifer R. Brown et al. HAEMATOLOGICA
- Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile
- (2017) Tjeerd Barf et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Practical recommendations for the choice of anticoagulants in the management of patients with atrial fibrillation on ibrutinib
- (2017) Khai Li Chai et al. LEUKEMIA & LYMPHOMA
- Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials
- (2017) Jennifer R. Brown et al. HAEMATOLOGICA
- Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience
- (2016) A. R. Mato et al. BLOOD
- Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells
- (2016) Viralkumar Patel et al. CLINICAL CANCER RESEARCH
- Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth
- (2016) Jun Chen et al. MOLECULAR CANCER THERAPEUTICS
- Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
- (2016) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
- (2015) Jan A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling
- (2014) J. R. McMullen et al. BLOOD
- Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
- (2014) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia
- (2012) M. F. M. de Rooij et al. BLOOD
- Treatment of elderly patients with chronic lymphocytic leukemia
- (2009) Barbara Eichhorst et al. LEUKEMIA & LYMPHOMA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now